BACKGROUND: HSP90 chaperones molecules critical for cell survival and malignant progression, including mutated B-raf. HSP90-targeting agents are in clinical trials. No large studies have been conducted on expression of HSP90 in melanomas. MATERIALS AND METHODS: Tissue microarrays containing 414 nevi, 198 primary and 270 metastatic melanomas were assessed using our automated quantitative analysis (AQUA) method of in situ protein measurement; we use S-100 to define pixels as melanocytes (tumor mask) within the array spot, and measure HSP90 expression within the mask using Cy5-conjugated antibodies. RESULTS: HSP90 expression was higher in melanomas than nevi (P < 0.0001) and higher in metastatic than primary specimens (P < 0.0001). No association was seen between high HSP90 expression and survival in the primary or metastatic patient subsets. In primary melanomas, high HSP90 expression was associated with higher Clark level (P = 0.0167) and increased Breslow depth (P < 0.0001). CONCLUSIONS: HSP90 expression was significantly higher in tumors than nevi and was associated with disease progression, indicating that it might be a valuable drug target in melanoma, as well as a useful diagnostic marker. Prospective studies are needed to confirm the diagnostic role of HSP90, as well as the predictive role of HSP90 expression in patients treated with HSP90 inhibitors.
BACKGROUND:HSP90 chaperones molecules critical for cell survival and malignant progression, including mutated B-raf. HSP90-targeting agents are in clinical trials. No large studies have been conducted on expression of HSP90 in melanomas. MATERIALS AND METHODS: Tissue microarrays containing 414 nevi, 198 primary and 270 metastatic melanomas were assessed using our automated quantitative analysis (AQUA) method of in situ protein measurement; we use S-100 to define pixels as melanocytes (tumor mask) within the array spot, and measure HSP90 expression within the mask using Cy5-conjugated antibodies. RESULTS:HSP90 expression was higher in melanomas than nevi (P < 0.0001) and higher in metastatic than primary specimens (P < 0.0001). No association was seen between high HSP90 expression and survival in the primary or metastatic patient subsets. In primary melanomas, high HSP90 expression was associated with higher Clark level (P = 0.0167) and increased Breslow depth (P < 0.0001). CONCLUSIONS:HSP90 expression was significantly higher in tumors than nevi and was associated with disease progression, indicating that it might be a valuable drug target in melanoma, as well as a useful diagnostic marker. Prospective studies are needed to confirm the diagnostic role of HSP90, as well as the predictive role of HSP90 expression in patients treated with HSP90 inhibitors.
Authors: Yashu Liu; Jintang He; Xaiolei Xie; Gang Su; Seagal Teitz-Tennenbaum; Michael S Sabel; David M Lubman Journal: J Proteome Res Date: 2010-10-20 Impact factor: 4.466
Authors: Giovanna Speranza; Larry Anderson; Alice P Chen; Khanh Do; Michelle Eugeni; Marcie Weil; Larry Rubinstein; Eva Majerova; Jerry Collins; Yvonne Horneffer; Lamin Juwara; Jennifer Zlott; Rachel Bishop; Barbara A Conley; Howard Streicher; Joseph Tomaszewski; James H Doroshow; Shivaani Kummar Journal: Invest New Drugs Date: 2017-08-12 Impact factor: 3.850
Authors: Harriet M Kluger; Christopher R Zito; Meaghan L Barr; Marina K Baine; Veronica L S Chiang; Mario Sznol; David L Rimm; Lieping Chen; Lucia B Jilaveanu Journal: Clin Cancer Res Date: 2015-03-18 Impact factor: 12.531
Authors: H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer Journal: Ann Oncol Date: 2009-08 Impact factor: 32.976